CA2779518A1 - Gastroretentive oral high dose zinc preparations - Google Patents

Gastroretentive oral high dose zinc preparations Download PDF

Info

Publication number
CA2779518A1
CA2779518A1 CA2779518A CA2779518A CA2779518A1 CA 2779518 A1 CA2779518 A1 CA 2779518A1 CA 2779518 A CA2779518 A CA 2779518A CA 2779518 A CA2779518 A CA 2779518A CA 2779518 A1 CA2779518 A1 CA 2779518A1
Authority
CA
Canada
Prior art keywords
zinc
pharmaceutical composition
composition
human
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2779518A
Other languages
English (en)
French (fr)
Inventor
George J. Brewer
Steve H. Kanzer
Max Lyon
David A. Newsome
Dennis Crouch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theriva Biologics Inc
Original Assignee
Synthetic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthetic Biologics Inc filed Critical Synthetic Biologics Inc
Publication of CA2779518A1 publication Critical patent/CA2779518A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2779518A 2009-11-01 2010-11-01 Gastroretentive oral high dose zinc preparations Abandoned CA2779518A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25703409P 2009-11-01 2009-11-01
US61/257,034 2009-11-01
PCT/US2010/054981 WO2011053917A2 (en) 2009-11-01 2010-11-01 Gastroretentive oral high dose zinc preparations

Publications (1)

Publication Number Publication Date
CA2779518A1 true CA2779518A1 (en) 2011-05-05

Family

ID=43923047

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2779518A Abandoned CA2779518A1 (en) 2009-11-01 2010-11-01 Gastroretentive oral high dose zinc preparations

Country Status (6)

Country Link
US (2) US20110212189A1 (enExample)
EP (1) EP2493484A4 (enExample)
JP (1) JP2013509443A (enExample)
AU (1) AU2010313216A1 (enExample)
CA (1) CA2779518A1 (enExample)
WO (1) WO2011053917A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016088816A1 (ja) * 2014-12-03 2016-06-09 ノーベルファーマ株式会社 酢酸亜鉛水和物錠及びその製造方法
MX2018013568A (es) * 2016-05-06 2019-03-14 Physicians Seal Llc Composiciones de suministro gastrico flotante de zinc.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105792A (en) * 1960-11-29 1963-10-01 Warner Lambert Pharmaceutical Stable effervescent compositions and method of preparing same
SE393532B (sv) * 1974-05-02 1977-05-16 Draco Ab Sett att framstella en farmaceutisk zinkberedning for astadkommande av en smaklig, fordragbar, peroral zinklosning innehallande ett zinkkomplex
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
HU217125B (hu) * 1993-03-10 1999-11-29 Béres Rt. Cukor- és nátriummentes pezsgőtabletta és -granulátum és eljárás azok előállítására
US6660297B2 (en) * 2001-03-23 2003-12-09 Bausch & Lomb Incorporated Nutritional supplement to treat macular degeneration
FR2884420B1 (fr) * 2005-04-13 2007-07-06 Labcatal Sa Nouvelle utilisation du gluconate de lithium pour le traitement de l'hidradenite suppuree
WO2007084818A2 (en) * 2006-01-10 2007-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
HUE029222T2 (en) * 2006-01-27 2017-02-28 Univ Yale Fast acting gastric acid secretion inhibitor
ITMI20061522A1 (it) * 2006-08-01 2008-02-02 Difass S A Composizione ad attivita' antiossidante ed antiglicante migliorata
ZA200903854B (en) * 2008-06-19 2011-02-23 Univ Of The Witwatesrand Johannesburg A gastroretentive pharmaceutical dosage form

Also Published As

Publication number Publication date
WO2011053917A3 (en) 2011-10-06
AU2010313216A1 (en) 2012-06-14
EP2493484A4 (en) 2013-03-27
EP2493484A2 (en) 2012-09-05
US20110212189A1 (en) 2011-09-01
WO2011053917A2 (en) 2011-05-05
US20120058055A1 (en) 2012-03-08
JP2013509443A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
RU2460340C2 (ru) Повышение стабильности витаминных и минеральных добавок
US11278591B2 (en) Compositions comprising choline
PT2222285T (pt) Composições farmacêuticas
WO2013026000A1 (en) Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
MXPA06000873A (es) Formulacion de liberacion inmediata de composiciones farmaceuticas labiles a acido.
CN101309688A (zh) 持续释放β-丙氨酸的组合物和方法
CA2561856A1 (en) Compressed composition comprising magnesium salt
WO2010008976A2 (en) Combined calcium, magnesium and vitamin d supplements
Chen et al. Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia
MX2015001930A (es) Preparacion farmaceutica solida que contiene levotiroxina.
ES2640816T3 (es) Utilización de una matriz para administración oral de magnesio de liberación prolongada y composición que contiene esta matriz
US20180015080A1 (en) Compositions and methods for treatment in parkinson's disease patients
ES2300452T3 (es) Comprimido ingerible que contiene paracetamol.
ES2586930T3 (es) Composición para el tratamiento de la esterilidad
WO2018045244A1 (en) Magnesium biotinate compositions and methods of use
US20120283320A1 (en) Stable, water-insoluble r-(+)-alpha-lipoic acid salt useful for the treatment of diabetes mellitus and its co-morbidities
CA2779518A1 (en) Gastroretentive oral high dose zinc preparations
CN101129351A (zh) 一种补铁剂组合物,其制备方法和应用
EP2805724B1 (en) Magnesium oxide hydrate-containing products and uses thereof
JP2022102122A (ja) 医薬組成物及びピレンゼピン塩酸塩水和物の安定化方法
JP2006199640A (ja) １日２回服用型経口投与製剤
KR20190027987A (ko) 에너지보급 및 근무력증 예방 및 개선용 경구투여용 시트룰린 말레이트 고형제제 조성물
JP2024037149A (ja) ラサギリン含有製剤の崩壊性の改善方法
KR20240137366A (ko) 중탄산나트륨을 포함하는 운동수행능력 개선용 또는 위장관 장해 개선용 장용성 제제
WO2023031946A1 (en) Effervescent pharmaceutical composition of ascorbic acid and zinc

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20161102